

May 22, 2024



PDRadiopharma Inc.

## Announcement of listing on the NHI Drug Price Standard of AMYViD<sup>®</sup>, a PET Imaging Agent for Detecting Beta Amyloid

*\*This release is an English translation of “アミロイドPET 検査用イメージング剤「アミヴィット<sup>®</sup>静注」薬価基準収載のお知らせ”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – May 22, 2024 - PDRadiopharma Inc. (President: Susumu Tanahashi, Headquarters: Chuo-ku, Tokyo, Japan) today announced that AMYViD<sup>®</sup> Injection (generic name: florbetapir (<sup>18</sup>F)) has been listed on the NHI Drug Price Standard in Japan.

The amyloid PET\* imaging procedure including the use of AMYViD<sup>®</sup> Injection is reimbursed by National Health Insurance from December 20, 2023 in conjunction with the insurance coverage of lecanemab to treat dementia in Japan. As a result of the revision of medical fees in FY2024, the fee for amyloid PET imaging was separated into a pharmaceutical fee and a technical fee for PET imaging. From June 1, 2024, a drug price will be applied to AMYViD<sup>®</sup> Injection, a PET imaging agent for detecting beta amyloid, as the pharmaceutical fee

### Product Overview

- Product name: AMYViD<sup>®</sup> Injection
- Indication: Visualization of beta amyloid plaques in the brain of patients with mild cognitive impairment or suspected to have dementia due to Alzheimer's disease
- Date of drug price listing: May 22, 2024
- Drug price application date: June 1, 2024
- Drug Price: JPY184,203 (370MBq bottle)

With the prevalence of dementia rapidly increasing due to an aging population, the medical treatment of dementia has entered a new era with the emergence of novel therapeutics. PDRadiopharma is committed to contributing to the advancement of dementia treatment options by providing innovative diagnostics and will continue to support patients and their families suffering from dementia.

\* PET: Positron Emission Tomography

**About AMYViD® Injection (generic name: florbetapir(18F))**

AMYViD® Injection obtained marketing authorization in December 2016 as the first flexible-dose™ formulation which differs from conventional radiopharmaceuticals in Japan. The indication for patients with suspected mild cognitive impairment due to Alzheimer's disease was expanded on August 31, 2023. AMYViD® is a registered trademark of Avid Radiopharmaceuticals, Inc.

**About PDRadiopharma**

PDRadiopharma has been providing high-quality radiopharmaceuticals since 1968. Our mission is to improve the lives of patients through the development of innovative diagnostics and therapeutics using radiopharmaceuticals. Currently, we domestically market 19 SPECT diagnostics, 2 PET diagnostics, and 8 therapeutic drugs (3 product categories). For more information, please visit <https://www.pdradiopharma.com/>

Inquiries:

PeptiDream Inc.

Contact: Yuko Okimoto, IR & Public Affairs

Email: [info@peptidream.com](mailto:info@peptidream.com)